All conditions

Transverse Myelitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

183
Trials on record
49
Recruiting now
1
Australian sites
6
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Transverse Myelitis →

Get alerts when Transverse Myelitis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Transverse Myelitis

Transverse myelitis is a condition where the spinal cord becomes inflamed. This inflammation can disrupt the signals that travel up and down the spinal cord between the brain and the rest of the body. As a result, people may experience weakness or difficulty moving their arms or legs, changes in sensation such as numbness or tingling, and sometimes problems with bladder or bowel control. The symptoms can develop over a few hours to a few weeks, and they can range from mild to quite severe. In some cases, transverse myelitis occurs on its own, while in others it may be linked to an underlying condition such as multiple sclerosis, an infection, or an autoimmune disorder.

Transverse myelitis is considered a rare condition. In Australia, it is estimated to affect roughly one to five people per 100,000, and it can occur at any age, including in children. It does not strongly favour one sex over the other, and it can affect people from all backgrounds. Because it is relatively uncommon, many Australians who receive this diagnosis find that their local neurologist or hospital team may work alongside specialists in larger centres to confirm the diagnosis and plan care.

When someone is diagnosed, doctors generally focus first on reducing the inflammation in the spinal cord, which often involves medications given in hospital. After that initial phase, a significant part of care typically involves rehabilitation — working with physiotherapists, occupational therapists, and other health professionals to help regain as much function as possible. Recovery varies a great deal from person to person; some people recover well, while others may have longer-lasting effects. Your medical team is the best source of guidance about what to expect in your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Transverse Myelitis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Transverse Myelitis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Transverse Myelitis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Transverse Myelitis by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

Clinical trials for Transverse Myelitis

Showing 53 of 53 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02003144 · Alexion Pharmaceuticals, Inc. Phase 3 · 20 countries Completed
Completed Phase 3 Est. completion 12 July 2021
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇨🇴 CO🇭🇷 HR🇨🇿 CZ🇩🇰 DK🇩🇪 DE +12 more

Who might be able to join this trial: - You must have already completed a previous clinical trial called ECU-NMO-301. - You must be willing and able to give your written agreement (consent) to take part. Who may not be able to join: - You cannot join if you left the ECU-NMO-301 trial early because of a side effect or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02200770 · MedImmune LLC Phase 3 · 25 countries Completed
Completed Phase 3 Est. completion 26 October 2018
🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇴 CO🇨🇿 CZ🇪🇪 EE🇩🇪 DE Hong Kong +17 more

**Who might be able to join this trial:** - You are a man or woman aged 18 or older who has been diagnosed with NMO or NMOSD (a rare disease affecting the spinal cord and optic nerves) - Your NMO/NMOSD has been confirmed by blood tests (either positive or negative for a protein called AQP4-IgG), and you have had at le...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04201262 · Alexion Pharmaceuticals, Inc. Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 15 March 2022
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +5 more

**Who might be able to join this trial:** - You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) and have tested positive for a specific antibody called anti-aquaporin-4 (confirm with trial site if unsure about your test results) - You have had at least 1 attack or relapse of your condition withi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06312644 · Alexion Pharmaceuticals, Inc. Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 11 July 2034
🇦🇺 AU🇫🇷 FR🇩🇪 DE🇮🇹 IT🇰🇷 KR🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You must have a confirmed pregnancy (either current or past) that qualifies for the study. - You (or your parent/legal guardian if you are a minor) must be willing and able to sign a consent form before joining. - You must be willing to share your contact information with th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT01892345 · Alexion Pharmaceuticals, Inc. Phase 3 · 18 countries Terminated
Terminated Phase 3 Est. completion 17 July 2018
🇦🇷 AR🇦🇺 AU🇭🇷 HR🇨🇿 CZ🇩🇰 DK🇩🇪 DE Hong Kong🇮🇹 IT +10 more

Who might be able to join this trial: - You are 18 years of age or older, either male or female - You have been diagnosed with NMO (Neuromyelitis Optica) or a related condition called NMOSD - You have tested positive for a specific antibody called AQP4 (confirm with trial site) - You have had at least 2 relapses (flare...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03011541 · MD Stem Cells Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇦🇹 AT🇦🇪 AE🇺🇸 US

**Who might be able to join this trial:** - You have confirmed, documented damage to your retina or optic nerve that is unlikely to get better on its own, OR you have damage that is getting worse over time along with reduced vision (20/30 or worse) and/or an abnormal visual field test in one or both eyes. - If you have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03887273 · Q Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand what the study involves and are willing to sign a consent form agreeing to participate and to allow their health information to be used. - People who live close enough to the trial centre, or have a reliable way to travel there. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03900221 · Hospices Civils de Lyon Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 12 August 2036
🇫🇷 FR Martinique

**Who might be able to join this trial:** - You have been diagnosed with Multiple Sclerosis (MS), confirmed using recognised medical guidelines (called McDonald criteria) - Your MS can be of any type, including a single attack, relapsing-remitting, secondary progressive, or primary progressive MS - You have a conditio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04106830 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are between 16 and 75 years old - You have been diagnosed with a condition involving inflammation or damage to the protective coating of nerves in the brain or spinal cord (such as MS or a related condition) - Information about your health and symptoms from when your conditio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04561557 · Tongji Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 22 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with one of the following conditions that has not responded well to standard treatments: a specific type of optic neuromyelitis (AQP4-positive NMOSD), myasthenia gravis (MG), chronic inflammatory nerve...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04721717 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older, have some form of paralysis, and live in the community (not in a hospital or care facility) - Your paralysis was caused by an injury or accident, or by a condition such as spinal cord injury, head injury, stroke, multiple sclerosis, transverse m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05004493 · Charles M Knudson Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

"Who might be able to join this trial: - You are currently receiving plasma exchange therapy (a treatment where blood is filtered and plasma is replaced) Who may not be able to join: - No specific exclusion criteria were listed in the available information (confirm with trial site) Important: Always verify eligibilit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05017142 · University of Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2071
🇨🇭 CH

**Who might be able to join this trial:** - You live and/or receive medical care in Switzerland - You were diagnosed with one of the listed brain or nervous system conditions on or after 2005, and your symptoms first began before you turned 18 - You (and/or your legal guardian, if applicable) are willing and able to p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05145361 · Shanghai Pharmaceuticals Holding Co., Ltd Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) and have tested positive for a specific antibody called anti-AQP4 in a screening blood test. - You have had at least 1 documented relapse (a flare-up of symptoms) in the 12 months b...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05154370 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇳 CN

Who might be able to join this trial: - People of any age and any sex are welcome to apply. - You must have been diagnosed with at least one of the following conditions: clinically isolated syndrome (CIS), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease (MOGAD),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05199688 · Hoffmann-La Roche Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 31 March 2027
🇦🇷 AR🇨🇳 CN🇫🇷 FR🇮🇹 IT🇲🇽 MX🇵🇱 PL Turkey (Türkiye)🇬🇧 GB +1 more

**Who might be able to join this trial:** - Children between 2 and 11 years old (inclusive) at the time of screening - Children who weigh at least 10 kg (approximately 22 pounds) at the time of screening - Girls who have started their periods must agree to either avoid sexual intercourse or use reliable birth control...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05204459 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 November 2041
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Multiple Sclerosis (MS), a clinically isolated syndrome (CIS), or a radiologically isolated syndrome (RIS) - You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) (confirm with trial site) - You have been diagnosed with a con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05349006 · Hospices Civils de Lyon Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 12 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have had your first episode of a condition where the protective coating around your brain or spinal cord nerves was attacked, and this happened within the last 3 months - Your blood test came back positive for MOG antibodies (a specific pro...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05491525 · Urovant Sciences GmbH Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2030
🇧🇪 BE🇨🇦 CA🇭🇷 HR🇩🇰 DK🇬🇪 GE🇯🇴 JO🇱🇻 LV🇱🇹 LT +8 more

**Who might be able to join this trial:** - The participant must be a child or teenager between 2 and under 18 years old, and must weigh at least 11 kg (about 24 lbs) at the screening appointment. - The participant must have been diagnosed with neurogenic detrusor overactivity (a bladder control condition caused by ne...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05504694 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of NMOSD (Neuromyelitis Optica Spectrum Disorder) confirmed by a positive AQP4-IgG blood test. - You have had at least 2 relapses (flare-ups) in the past 2 years, with at least 1 of those happening in the last 12 months. - You are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05549258 · Amgen Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 13 April 2027
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇫🇷 FR🇳🇱 NL🇵🇱 PL🇷🇸 RS🇪🇸 ES +3 more

**Who might be able to join this trial:** - Children and teenagers between 2 and under 18 years old, who weigh at least 15 kg (about 33 lbs), regardless of sex. - Participants who have tested positive for a specific antibody called anti-AQP4-IgG in their blood and have been diagnosed with a condition called NMOSD (Neu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05566769 · Ad scientiam Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇫🇷 FR🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) that has tested positive for a specific protein marker called AQP4, based on 2015 international diagnostic guidelines - You are already receiving treatment for NMOSD...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05792462 · Tianjin Medical University General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with NMO (Neuromyelitis Optica) or a related condition called NMO spectrum disorder, based on specific 2015 diagnostic guidelines - You have had at least one severe episode (called an "attack") in the past year that need...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05909761 · Amgen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2032
🇺🇸 US

Who might be able to join this trial: - You are willing and able to give your consent to take part in the study - You are a woman who is able to become pregnant and have been diagnosed with, or are suspected to have, a condition called NMOSD (a rare disease affecting the nerves and spinal cord) - You were exposed to a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05966467 · Alexion Pharmaceuticals, Inc. Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 27 September 2029
🇦🇷 AR🇨🇦 CA🇨🇳 CN🇩🇪 DE🇮🇹 IT🇯🇵 JP🇰🇷 KR🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older when you sign up for the registry. - You must have a confirmed diagnosis of a specific type of neuromyelitis optica spectrum disorder (a rare condition affecting the spinal cord and optic nerves), confirmed by a positive AQP4 antibody test (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05982925 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You are able to give your consent to participate in English - You are able to have an MRI scan Who may not be able to join: - You have a medical reason that means you cannot safely have an MRI scan (such as certain metal implants or a pacemaker) (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06147258 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a spinal cord injury (either from an accident/injury or a medical condition) that has caused weakness in your arms or legs - You are over 18 years old - You have access to the internet and a computer or smartphone that can be used for video calls...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06249438 · RenJi Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old at the time of signing the consent form. - You have been diagnosed with one of the following conditions for at least 6 months: Lupus (SLE), Immune-Mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multip...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06280755 · icometrix Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇿 CZ🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with one of the following conditions: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), MOG Antibody Disease (MOGAD), Clinically Isolated Syndrome (CIS), or Radiologically Isolated Syndrome (RIS) (confirm with trial site if unsure wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06398158 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before any study activities begin - You must be a man or woman over 18 years of age - You must have been diagnosed with neuromyelitis optica spectrum disorder (a condition affecting the nerves and spinal cord), have tested p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413654 · Shanghai Jiaolian Drug Research and Development Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with NMOSD (Neuromyelitis Optica Spectrum Disorder). - You have had at least 1 relapse (flare-up) of NMOSD in the past year, or at least 2 relapses in the past 2 years. - If you are a woman who could become pregnant, your pregnancy test must be negati...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06453694 · Anastasia Vishnevetsky, MD, MPH Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with your **first-ever episode** of optic neuritis, confirmed by an MRI scan - Your vision changes (such as blurred vision or reduced sharpness) began **within the last 10 days** before joining the study — if both ey...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474520 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇨🇳 CN

**Who might be able to join this trial:** **For people with an inflammatory brain or spinal cord disease (IIDD group):** - People aged 18 to 65 years old (inclusive) who are able to understand the study, agree to take part, and allow their health information to be used in line with privacy laws - Both men and women ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06502015 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with certain inflammatory conditions affecting the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Idiopathic Inflammatory Myopa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06541626 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old and have been diagnosed with an inflammatory disease affecting the myelin (protective coating) of your brain or spinal cord - Your condition has been identified as one of the following: MS (Multiple Sclerosis), NMOSD, MOGAD, ADEM, clinicall...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06620809 · Tongji Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) based on recognised international criteria, and you have tested positive for a specific protein marker called AQP4 antibodies. - Your current symptoms started within the last 7 days, and you are expe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06680037 · TG Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** *For Multiple Sclerosis (MS) participants:* - You are between 18 and 60 years old - Your MS-related disability falls within a certain range, as measured by a standard disability scale called the EDSS (score between 3.0 and 6.5) — confirm with trial site if unsure what your sco...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06697535 · Guangzhou JOYO Pharma Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) based on the 2015 international diagnostic guidelines - Your blood tests show a positive result for a specific protein called AQP4-IgG (a marker linked to this condition) - You are currently experiencing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06763848 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with an acute (sudden/active) episode of a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). - You are between 18 and 65 years old (any gender is welcome). - A blood test has shown you carry a specific marker called AQP4-IgG, detected us...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780709 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) using specific 2015 medical guidelines - People at any level of disability are welcome — there are no restrictions based on how much the condition affects yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865274 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with MS (Multiple Sclerosis), NMOSD (Neuromyelitis Optica Spectrum Disorder), or MOGAD (Myelin Oligodendrocyte Glycoprotein Antibody Disease) and are receiving care at one of the participating medical centers - You are 18 years of age or older - You are ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06885957 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must be able to understand the goals and risks of the study, sign a consent form, and agree to your health information being used as required by privacy laws. - You must be between 18 and 65 years old (inclusive) at the time you sign the consent form, and any biological...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06939166 · Tianjin Huanhu Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older. - A specific blood test (flow cytometry) must show that certain markers called CD19 or BCMA are present on your B cells (a type of immune cell). - You must have been diagnosed with a neurological autoimmune disease that has come back or has not...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06941584 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with a condition called NMOSD (a disease affecting the brain and spinal cord) linked to a specific antibody called AQP4, and you also have at least one other autoimmune condition from a specific list (confirm with trial site) - You have been diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07022197 · Tianjin Medical University General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have a neuroimmune disease that has not responded well to treatment — specifically, it has not been controlled despite trying at least three different immune-suppressing medications for more than one year, OR you have had at least two relapses (flare-ups) in the past 12...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07085676 · Polina Stepensky Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2026
🇮🇱 IL

**Who might be able to join this trial:** - Adults between 18 and 80 years old (people aged 75 or older would need an additional geriatric health assessment before being considered) - People diagnosed with Systemic Lupus Erythematosus (SLE) whose disease is severe and active, and whose condition has not responded well...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07100990 · Mayo Clinic Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2029
🇺🇸 US

**Optic Neuritis Sub-Trial (for people with sudden vision loss due to optic nerve inflammation)** Who might be able to join this trial: - People aged 18 or older - People whose MRI scan shows new inflammation or swelling of one or both optic nerves, consistent with a diagnosis of optic neuritis - People whose vision i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07202494 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 May 2030
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older (any gender). - You must not have any serious uncontrolled health conditions, such as cancer, autoimmune disease, liver failure, severe high blood pressure, or serious heart rhythm problems. - You must not have a serious long-term mental healt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07377305 · Tang-Du Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD), confirmed using recognised international diagnostic guidelines. - You experience nerve-related pain, with a score of 4 or higher on a standard screening tool used to identify this...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07410039 · Chinese PLA General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (any gender) - You have been diagnosed with a condition called NMOSD (Neuromyelitis Optica Spectrum Disorder) according to recognised 2015 international guidelines, and a specific blood test (AQP4-IgG) has come back positive - You are curr...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07420296 · Tianjin Medical University General Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older - You have been officially diagnosed with a condition called AQP4-IgG-positive NMOSD (a disease affecting the spinal cord and optic nerves), confirmed using the 2015 diagnostic guidelines - A blood test has shown that you carry a specific antibody...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07526493 · Tongji Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 75 years old of any gender. - People who are able and willing to use medically approved contraception or abstinence during the treatment period and for at least 6 months afterward; for women who could become pregnant, a negative pregnancy blood test wit...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07653984 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇨🇳 CN

**Who might be able to join this trial:** *For the patient group (up to 50 participants):* - You are a woman between the ages of 20 and 55 who is able to become pregnant - You are willing to take part and have given your agreement in writing - Your full personal and medical information is available - You have been for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Transverse Myelitis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Spinal Life Australia is the relevant national body for transverse myelitis, within its broader work on spinal conditions.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.